Cargando…
Single Hormone Receptor-Positive Metaplastic Breast Cancer: Similar Outcome as Triple-Negative Subtype
BACKGROUND: Metaplastic breast cancer (MBC) is a rare and aggressive subtype of the breast. To understand the characteristics and prognosis of single hormone receptor-positive (HR+) MBC (estrogen receptor-positive [ER+]/progesterone receptor-negative [PR-] and ER-/PR+), we compared these tumors to d...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8105402/ https://www.ncbi.nlm.nih.gov/pubmed/33972826 http://dx.doi.org/10.3389/fendo.2021.628939 |
_version_ | 1783689604668325888 |
---|---|
author | Mao, Jinqian Hu, Jin Zhang, Yanting Shen, Jian Dong, Fang Zhang, Ximeng Ming, Jie Huang, Tao Run, Xiaoqin |
author_facet | Mao, Jinqian Hu, Jin Zhang, Yanting Shen, Jian Dong, Fang Zhang, Ximeng Ming, Jie Huang, Tao Run, Xiaoqin |
author_sort | Mao, Jinqian |
collection | PubMed |
description | BACKGROUND: Metaplastic breast cancer (MBC) is a rare and aggressive subtype of the breast. To understand the characteristics and prognosis of single hormone receptor-positive (HR+) MBC (estrogen receptor-positive [ER+]/progesterone receptor-negative [PR-] and ER-/PR+), we compared these tumors to double HR+ tumors as well as HR- tumors. PATIENTS AND METHODS: The Surveillance, Epidemiology, and End Results database was used to analyze MBC between 1975 and 2016. The effect of HR status was evaluated using a multivariate Cox regression model. RESULTS: We included 3369 patients with a median follow-up time of 42 months (range 0-322 months). In this study, 280 (8.3%) cases were double HR+ tumors, 2597 (77.1%) were double HR- tumors, and 492 (14.6%) cases were single HR+ tumors, of which 159 (4.7%) cases were ER-/PR+ tumors and 333 (9.9%) were ER+/PR- tumors. On multivariate Cox analysis, the prognosis was related to age, race/ethnicity, tumor grade, TNM stage, and surgery. HR status remained no impact on breast cancer-specific survival (BCSS). In the Kaplan-Meier curve, HR status was not associated with better BCSS or overall survival (OS). In patients without HER2 overexpression, the BCSS and OS of ER+/PR- and ER-/PR+ tumors were not significantly different from that of ER-/PR- and ER+/PR+ tumors. The difference remains no significant in patients with HER2 overexpression. CONCLUSIONS: In comparison with both ER-/PR- and ER+/PR+ tumors, we have identified clinically and biologically distinct features of single HR+ tumors. In patients with or without HER2 overexpression, the prognosis of single HR+ tumors was similar to ER-/PR- and ER+/PR+ tumors. |
format | Online Article Text |
id | pubmed-8105402 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-81054022021-05-09 Single Hormone Receptor-Positive Metaplastic Breast Cancer: Similar Outcome as Triple-Negative Subtype Mao, Jinqian Hu, Jin Zhang, Yanting Shen, Jian Dong, Fang Zhang, Ximeng Ming, Jie Huang, Tao Run, Xiaoqin Front Endocrinol (Lausanne) Endocrinology BACKGROUND: Metaplastic breast cancer (MBC) is a rare and aggressive subtype of the breast. To understand the characteristics and prognosis of single hormone receptor-positive (HR+) MBC (estrogen receptor-positive [ER+]/progesterone receptor-negative [PR-] and ER-/PR+), we compared these tumors to double HR+ tumors as well as HR- tumors. PATIENTS AND METHODS: The Surveillance, Epidemiology, and End Results database was used to analyze MBC between 1975 and 2016. The effect of HR status was evaluated using a multivariate Cox regression model. RESULTS: We included 3369 patients with a median follow-up time of 42 months (range 0-322 months). In this study, 280 (8.3%) cases were double HR+ tumors, 2597 (77.1%) were double HR- tumors, and 492 (14.6%) cases were single HR+ tumors, of which 159 (4.7%) cases were ER-/PR+ tumors and 333 (9.9%) were ER+/PR- tumors. On multivariate Cox analysis, the prognosis was related to age, race/ethnicity, tumor grade, TNM stage, and surgery. HR status remained no impact on breast cancer-specific survival (BCSS). In the Kaplan-Meier curve, HR status was not associated with better BCSS or overall survival (OS). In patients without HER2 overexpression, the BCSS and OS of ER+/PR- and ER-/PR+ tumors were not significantly different from that of ER-/PR- and ER+/PR+ tumors. The difference remains no significant in patients with HER2 overexpression. CONCLUSIONS: In comparison with both ER-/PR- and ER+/PR+ tumors, we have identified clinically and biologically distinct features of single HR+ tumors. In patients with or without HER2 overexpression, the prognosis of single HR+ tumors was similar to ER-/PR- and ER+/PR+ tumors. Frontiers Media S.A. 2021-04-23 /pmc/articles/PMC8105402/ /pubmed/33972826 http://dx.doi.org/10.3389/fendo.2021.628939 Text en Copyright © 2021 Mao, Hu, Zhang, Shen, Dong, Zhang, Ming, Huang and Run https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Endocrinology Mao, Jinqian Hu, Jin Zhang, Yanting Shen, Jian Dong, Fang Zhang, Ximeng Ming, Jie Huang, Tao Run, Xiaoqin Single Hormone Receptor-Positive Metaplastic Breast Cancer: Similar Outcome as Triple-Negative Subtype |
title | Single Hormone Receptor-Positive Metaplastic Breast Cancer: Similar Outcome as Triple-Negative Subtype |
title_full | Single Hormone Receptor-Positive Metaplastic Breast Cancer: Similar Outcome as Triple-Negative Subtype |
title_fullStr | Single Hormone Receptor-Positive Metaplastic Breast Cancer: Similar Outcome as Triple-Negative Subtype |
title_full_unstemmed | Single Hormone Receptor-Positive Metaplastic Breast Cancer: Similar Outcome as Triple-Negative Subtype |
title_short | Single Hormone Receptor-Positive Metaplastic Breast Cancer: Similar Outcome as Triple-Negative Subtype |
title_sort | single hormone receptor-positive metaplastic breast cancer: similar outcome as triple-negative subtype |
topic | Endocrinology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8105402/ https://www.ncbi.nlm.nih.gov/pubmed/33972826 http://dx.doi.org/10.3389/fendo.2021.628939 |
work_keys_str_mv | AT maojinqian singlehormonereceptorpositivemetaplasticbreastcancersimilaroutcomeastriplenegativesubtype AT hujin singlehormonereceptorpositivemetaplasticbreastcancersimilaroutcomeastriplenegativesubtype AT zhangyanting singlehormonereceptorpositivemetaplasticbreastcancersimilaroutcomeastriplenegativesubtype AT shenjian singlehormonereceptorpositivemetaplasticbreastcancersimilaroutcomeastriplenegativesubtype AT dongfang singlehormonereceptorpositivemetaplasticbreastcancersimilaroutcomeastriplenegativesubtype AT zhangximeng singlehormonereceptorpositivemetaplasticbreastcancersimilaroutcomeastriplenegativesubtype AT mingjie singlehormonereceptorpositivemetaplasticbreastcancersimilaroutcomeastriplenegativesubtype AT huangtao singlehormonereceptorpositivemetaplasticbreastcancersimilaroutcomeastriplenegativesubtype AT runxiaoqin singlehormonereceptorpositivemetaplasticbreastcancersimilaroutcomeastriplenegativesubtype |